AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36975019 — intervention group
Group type: COMPARATOR
Intervention: Usual care or no intervention on blood pressure (placebo)
Number of subjects: 22885
Study 36975019 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive agents
Number of subjects: 22885
Study 36975019 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense blood pressure control
Number of subjects: 22885
Study 36975201 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene therapy (GT) for SCD
Number of subjects: 104
Study 36975201 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge about GT
Number of subjects: 104
Study 36975207 — intervention group
Group type: EXPERIMENTAL
Intervention: Third dose of mRNA COVID-19 vaccine
Number of subjects: 106
Study 36975207 — intervention group
Group type: EXPERIMENTAL
Intervention: Fourth dose of mRNA COVID-19 vaccine
Number of subjects: 106
Study 36975207 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster doses (third and fourth doses)
Number of subjects: 106
Study 36975308 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary (TIMP-2) × (IGFBP7)
Number of subjects: 300
Study 36975369 — intervention group
Group type: EXPERIMENTAL
Intervention: V160 vaccine
Number of subjects: 18
Study 36975369 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 36975790 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifurtimox 60-day regimen (10 to 20 mg/kg/day for patients aged <12 years and body weight <40 kg; 8 to 10 mg/kg/day for those aged ≥12 years and body weight ≥40 kg)
Number of subjects: 0
Study 36975790 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifurtimox 30-day regimen (10 to 20 mg/kg/day for patients aged <12 years and body weight <40 kg; 8 to 10 mg/kg/day for those aged ≥12 years and body weight ≥40 kg)
Number of subjects: 0
Study 36975790 — intervention group
Group type: COMPARATOR
Intervention: Historical placebo control group
Number of subjects: 0
Study 36975790 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifurtimox (both regimens)
Number of subjects: 0
Study 36976258 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic Acid (FA) supplementation
Number of subjects: 622
Study 36976258 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation
Number of subjects: 622
Study 36976258 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined FA and Creatine supplementation
Number of subjects: 622
Study 36976258 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 622
Study 36976326 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal electrical stimulation (IVES), performed 3 days a week for 8 weeks, 24 sessions, 20 minutes each
Number of subjects: 48
Study 36976326 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal electrical stimulation (IVES)
Number of subjects: 48
Study 36976619 — intervention group
Group type: EXPERIMENTAL
Intervention: SteWARdS Antibiotic Defence app
Number of subjects: 400
Study 36976619 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 400
Study 36976624 — intervention group
Group type: EXPERIMENTAL
Intervention: TelePhys group (monthly telemedicine consultation focusing on physical activity coaching)
Number of subjects: 90
Study 36976624 — intervention group
Group type: EXPERIMENTAL
Intervention: TeleDiet group (monthly telemedicine consultation involving diet coaching)
Number of subjects: 90
Study 36976624 — intervention group
Group type: COMPARATOR
Intervention: Both groups (TelePhys and TeleDiet)
Number of subjects: 90
Study 36976630 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) intervention administered by trained nurses, details on dosage and duration not specified.
Number of subjects: 0
Study 36976630 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) intervention with caregiver participation, details on dosage and duration not specified.
Number of subjects: 0
Study 36976630 — intervention group
Group type: COMPARATOR
Intervention: Motivational Interviewing (MI) intervention administered only to individual patients, details on dosage and duration not specified.
Number of subjects: 0
Study 36976630 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving standard care without MI, details on dosage and duration not specified.
Number of subjects: 0
Study 36976651 — intervention group
Group type: EXPERIMENTAL
Intervention: Elexacaftor/tezacaftor/ivacaftor (ETI)
Number of subjects: 236
Study 36976655 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 screening
Number of subjects: 0
Study 36977289 — intervention group
Group type: EXPERIMENTAL
Intervention: Ficlatuzumab with Cetuximab
Number of subjects: 60
Study 36977289 — intervention group
Group type: COMPARATOR
Intervention: Ficlatuzumab Monotherapy
Number of subjects: 60
Study 36977292 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-conserving therapy (BCT) including lumpectomies with negative margins followed by whole breast radiation with boost to all lumpectomy beds.
Number of subjects: 204
Study 36977292 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative MRI (n = 189)
Number of subjects: 204
Study 36977292 — intervention group
Group type: EXPERIMENTAL
Intervention: No preoperative MRI (n = 15)
Number of subjects: 204
Study 36977327 — intervention group
Group type: EXPERIMENTAL
Intervention: Epiretinal membrane
Number of subjects: 610
Study 36977327 — intervention group
Group type: EXPERIMENTAL
Intervention: Myopic retinoschisis
Number of subjects: 610
Study 36977327 — intervention group
Group type: EXPERIMENTAL
Intervention: Macular hole
Number of subjects: 610
Study 36977371 — intervention group
Group type: EXPERIMENTAL
Intervention: AMSA-guided CPR
Number of subjects: 31
Study 36977371 — intervention group
Group type: COMPARATOR
Intervention: Standard CPR
Number of subjects: 31
Study 36977536 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile application ACP programme and a 30 min interview with a trained intervention provider
Number of subjects: 264
Study 36977536 — intervention group
Group type: COMPARATOR
Intervention: Usual treatment
Number of subjects: 264
Study 36977629 — intervention group
Group type: EXPERIMENTAL
Intervention: Ecological momentary assessment (EMA) on irritability-related constructs and other mood and anxiety symptoms three times a day for 7 days.
Number of subjects: 152
Study 36977960 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritlecitinib
Number of subjects: 0
Study 36977960 — intervention group
Group type: COMPARATOR
Intervention: Statistical and POPPK simulation approaches
Number of subjects: 0
Study 36977972 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomimetic polyurethane-based scaffold
Number of subjects: 15
Study 36977981 — intervention group
Group type: EXPERIMENTAL
Intervention: Butorphanol
Number of subjects: 206
Study 36977981 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 206
Study 36978026 — intervention group
Group type: EXPERIMENTAL
Intervention: schiZotypy Autism Questionnaire (ZAQ)
Number of subjects: 500
Study 36978026 — intervention group
Group type: COMPARATOR
Intervention: Clinical diagnoses from interdisciplinary teams at specialised psychiatric clinics
Number of subjects: 500
Study 36978035 — intervention group
Group type: EXPERIMENTAL
Intervention: EDP plus ACBT
Number of subjects: 363
Study 36978035 — intervention group
Group type: EXPERIMENTAL
Intervention: Acapella plus ACBT
Number of subjects: 363
Study 36978035 — intervention group
Group type: COMPARATOR
Intervention: ACBT (control group)
Number of subjects: 363
Study 36978045 — intervention group
Group type: EXPERIMENTAL
Intervention: i-REBOUND programme receiving physical exercise and support for sustained engagement in physical activity through behavioural change techniques
Number of subjects: 120
Study 36978045 — intervention group
Group type: COMPARATOR
Intervention: Behavioural change techniques for physical activity
Number of subjects: 120
Study 36978066 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin (part of the TECOS trial)
Number of subjects: 0
Study 36978071 — intervention group
Group type: EXPERIMENTAL
Intervention: CHW-led CHORD intervention
Number of subjects: 559
Study 36978071 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 559
Study 36978080 — intervention group
Group type: EXPERIMENTAL
Intervention: Epicardial adipose tissue (EAT) thickness measurement
Number of subjects: 1554
Study 36978080 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP and GLS as mediators
Number of subjects: 1554
Study 36978080 — intervention group
Group type: EXPERIMENTAL
Intervention: EAT assessment
Number of subjects: 1554
Study 36978097 — intervention group
Group type: EXPERIMENTAL
Intervention: Offering three raw carrot batons and three cucumber sticks alongside children's main breakfast food each day for three weeks.
Number of subjects: 351
Study 36978097 — intervention group
Group type: COMPARATOR
Intervention: Usual breakfast provided in control nurseries.
Number of subjects: 351
Study 36978097 — intervention group
Group type: EXPERIMENTAL
Intervention: Data collection preference by nursery staff.
Number of subjects: 351
Study 36978099 — intervention group
Group type: EXPERIMENTAL
Intervention: Analgesic therapy for moderate/severe pain
Number of subjects: 63
Study 36978099 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal analgesia with opioids
Number of subjects: 63
Study 36978099 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioids alone
Number of subjects: 63
Study 36978099 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-based therapy
Number of subjects: 63
Study 36978099 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent therapy
Number of subjects: 63
Study 36978099 — intervention group
Group type: EXPERIMENTAL
Intervention: No therapy
Number of subjects: 63
Study 36978099 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain prevalence
Number of subjects: 63
Study 36978099 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain intensity
Number of subjects: 63
Study 36978099 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain management improvements
Number of subjects: 63
Study 36978128 — intervention group
Group type: EXPERIMENTAL
Intervention: 45,X
Number of subjects: 0
Study 36978128 — intervention group
Group type: EXPERIMENTAL
Intervention: 47,XXY
Number of subjects: 0
Study 36978128 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat and muscle tissues
Number of subjects: 0
Study 36978128 — intervention group
Group type: EXPERIMENTAL
Intervention: X chromosomal genes
Number of subjects: 0
Study 36978128 — intervention group
Group type: EXPERIMENTAL
Intervention: X chromosome number
Number of subjects: 0
Study 36979637 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic testing for DAO deficiency
Number of subjects: 0
Study 36979982 — intervention group
Group type: EXPERIMENTAL
Intervention: Telerehabilitation-Based Structured Home Program
Number of subjects: 43
Study 36979982 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 43
Study 36980529 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical risk factors used for treatment stratification in the EpSSG RMS 2005 protocol
Number of subjects: 0
Study 36980529 — intervention group
Group type: EXPERIMENTAL
Intervention: Current EpSSG overarching study for frontline and relapsed rhabdomyosarcoma (FaR-RMS NCT04625907)
Number of subjects: 0
Study 36981850 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive training (speed of processing, memory, reasoning)
Number of subjects: 0
Study 36981850 — intervention group
Group type: COMPARATOR
Intervention: No-contact control group
Number of subjects: 0
Study 36983145 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation (CR) fully immersive Virtual Reality (VR) recovery-oriented program plus conventional care
Number of subjects: 64
Study 36983145 — intervention group
Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 64
Study 36987384 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchronous multiple gastric cancer (SMGC)
Number of subjects: 14603
Study 36987384 — intervention group
Group type: COMPARATOR
Intervention: Single gastric cancer (GC)
Number of subjects: 14603
Study 36987384 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced gastric cancer (AGC) with SMGC
Number of subjects: 14603
Study 36987387 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive CIMT
Number of subjects: 50
Study 36987387 — intervention group
Group type: COMPARATOR
Intervention: Distributed CIMT
Number of subjects: 50
Study 36987440 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic myocarditis (n=17)
Number of subjects: 54
Study 36987440 — intervention group
Group type: COMPARATOR
Intervention: Symptomatic no myocarditis (n=17)
Number of subjects: 54
Study 36987440 — intervention group
Group type: COMPARATOR
Intervention: Asymptomatic (n=20)
Number of subjects: 54
Study 36987682 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided percutaneous nerve stimulation (PENS)
Number of subjects: 70
Study 36987682 — intervention group
Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 70
Study 36987703 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT)
Number of subjects: 70
Study 36987836 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 907828
Number of subjects: 0
Study 36987836 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin
Number of subjects: 0
Study 36987861 — intervention group
Group type: EXPERIMENTAL
Intervention: BBIBP-CorV inactivated SARS-CoV-2 vaccine
Number of subjects: 0
Study 36987929 — intervention group
Group type: EXPERIMENTAL
Intervention: edoxaban
Number of subjects: 21005
Study 36987929 — intervention group
Group type: COMPARATOR
Intervention: warfarin
Number of subjects: 21005
Study 36987929 — intervention group
Group type: EXPERIMENTAL
Intervention: hsTnT, NT-proBNP, GDF-15 (serial measurement)
Number of subjects: 21005
Study 36988304 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual Cognitive Processing Therapy for PTSD
Number of subjects: 223
Study 36988304 — intervention group
Group type: COMPARATOR
Intervention: Group Cognitive Processing Therapy for PTSD
Number of subjects: 223
Study 36988337 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation of ventilator protocols for low tidal volume ventilation (LTVV) in the ICU.
Number of subjects: 8692
Study 36988337 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation of ventilator protocols for low tidal volume ventilation (LTVV) in the ICU among patients with ARDS.
Number of subjects: 8692
Study 36988361 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (ITM) 0.3 mg
Number of subjects: 82
Study 36988361 — intervention group
Group type: COMPARATOR
Intervention: Erector spinae plane block (ESPB) with 0.25% bupivacaine
Number of subjects: 82
Study 36988483 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimization of Treatment and Management of Schizophrenia in Europe (OPTiMiSE) intervention, details not available
Number of subjects: 0
Study 36988592 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter arterialization of the deep veins
Number of subjects: 105
Study 36988594 — intervention group
Group type: EXPERIMENTAL
Intervention: Vedolizumab (300 mg intravenously on day 1 and at weeks 2, 6, 14, 22, and 30)
Number of subjects: 102
Study 36988594 — intervention group
Group type: EXPERIMENTAL
Intervention: Vedolizumab (300 mg intravenously)
Number of subjects: 102
Study 36988594 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 36988715 — intervention group
Group type: EXPERIMENTAL
Intervention: 80-kVp thin-section pancreatic CT
Number of subjects: 138
Study 36988715 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor response after neoadjuvant therapy
Number of subjects: 138
Study 36988757 — intervention group
Group type: EXPERIMENTAL
Intervention: ByCross® atherectomy device
Number of subjects: 39
Study 36988819 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterine lavage procedure with genetically screened euploid blastocysts
Number of subjects: 8
Study 36988819 — intervention group
Group type: COMPARATOR
Intervention: Standard in vitro fertilization (IVF) (implied control)
Number of subjects: 8
Study 36988824 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial-thickness non-advanced tunnel technique (TUN)
Number of subjects: 29
Study 36988824 — intervention group
Group type: COMPARATOR
Intervention: Coronally advanced flap (CAF)
Number of subjects: 29
Study 36988824 — intervention group
Group type: EXPERIMENTAL
Intervention: TUN
Number of subjects: 29
Study 36988824 — intervention group
Group type: COMPARATOR
Intervention: CAF
Number of subjects: 29
Study 36988936 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (cholecalciferol, 100 000 IU loading dose, followed by 20 000 IU/week)
Number of subjects: 122
Study 36988936 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study 36988936 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (cholecalciferol)
Number of subjects: 122
Study 36989027 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic brief intervention
Number of subjects: 329
Study 36989027 — intervention group
Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 329
Study 36989357 — intervention group
Group type: EXPERIMENTAL
Intervention: CAdVEC (ultralow dose, single intratumoral injection)
Number of subjects: 4
Study 36989829 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant systemic therapy (anti-PD1 and anti-CTLA4)
Number of subjects: 120
Study 36989829 — intervention group
Group type: COMPARATOR
Intervention: Upfront surgery
Number of subjects: 120
Study 36989884 — intervention group
Group type: EXPERIMENTAL
Intervention: AK109 (anti-VEGFR2 monoclonal antibody)
Number of subjects: 40
Study 36990111 — intervention group
Group type: EXPERIMENTAL
Intervention: Mizoribine (MZR)
Number of subjects: 239
Study 36990111 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide (CYC)
Number of subjects: 239
Study 36990125 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS-guided fine-needle biopsy (EUS-FNB) using 22-gauge Franseen tip or 25-gauge fork-tip needles
Number of subjects: 100
Study 36990125 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS-guided fine-needle biopsy (EUS-FNB)
Number of subjects: 100
Study 36990125 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS-guided fine-needle biopsy (EUS-FNB) for lymphoproliferative disease
Number of subjects: 100
Study 36990211 — intervention group
Group type: EXPERIMENTAL
Intervention: Refined SCR score using two genes (AKR1C3 and TCL1A) and four clinical parameters (previous experience of rejection, previous transplantation, sex of recipient, tacrolimus uptake)
Number of subjects: 588
Study 36990211 — intervention group
Group type: EXPERIMENTAL
Intervention: Refined SCR score validated in an external laboratory using qPCR and NanoString methods
Number of subjects: 588
Study 36990214 — intervention group
Group type: EXPERIMENTAL
Intervention: Covered stent after PTA
Number of subjects: 280
Study 36990214 — intervention group
Group type: COMPARATOR
Intervention: PTA alone
Number of subjects: 280
Study 36990225 — intervention group
Group type: EXPERIMENTAL
Intervention: Nordic group (NG)
Number of subjects: 250
Study 36990225 — intervention group
Group type: COMPARATOR
Intervention: Conventional group (CG)
Number of subjects: 250
Study 36990261 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anticoagulation (OAC) treatment
Number of subjects: 23121
Study 36990261 — intervention group
Group type: COMPARATOR
Intervention: No oral anticoagulation (no-OAC) treatment
Number of subjects: 23121
Study 36990275 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Care (EC; cPRO plus web-based symptom self-management intervention)
Number of subjects: 0
Study 36990275 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC; cPRO alone)
Number of subjects: 0
Study 36990274 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard acupuncture (SA; up to 15 treatment sessions across 12 weeks)
Number of subjects: 807
Study 36990274 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced acupuncture (EA; SA during first 12 weeks and up to 6 additional sessions across the following 12 weeks)
Number of subjects: 807
Study 36990274 — intervention group
Group type: COMPARATOR
Intervention: Usual medical care (UMC) alone
Number of subjects: 807
Study 36990468 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 78
Study 36990468 — intervention group
Group type: COMPARATOR
Intervention: Social support/education (SE)
Number of subjects: 78
Study 36990469 — intervention group
Group type: EXPERIMENTAL
Intervention: Adults with ADHD
Number of subjects: 64
Study 36990469 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 64
Study 36990475 — intervention group
Group type: EXPERIMENTAL
Intervention: VR-assisted cognitive behavioural therapy (VR-CBT)
Number of subjects: 102
Study 36990475 — intervention group
Group type: COMPARATOR
Intervention: Cognitive behavioural therapy (CBT)
Number of subjects: 102
Study 36990482 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerised diagnostic decision support systems (CDDS) used during diagnostic workup.
Number of subjects: 1184
Study 36990482 — intervention group
Group type: COMPARATOR
Intervention: Usual clinical care without access to CDDS during diagnostic workup.
Number of subjects: 1184
Study 36990482 — intervention group
Group type: EXPERIMENTAL
Intervention: CDDS usage during intervention periods.
Number of subjects: 1184
Study 36990481 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive fatigability
Number of subjects: 200
Study 36990481 — intervention group
Group type: EXPERIMENTAL
Intervention: Executive inhibition
Number of subjects: 200
Study 36990481 — intervention group
Group type: EXPERIMENTAL
Intervention: Imaging markers
Number of subjects: 200
Study 36990481 — intervention group
Group type: EXPERIMENTAL
Intervention: Inflammatory markers
Number of subjects: 200
Study 36990481 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-rated fatigue
Number of subjects: 200
Study 36990481 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal fluency
Number of subjects: 200
Study 36990481 — intervention group
Group type: EXPERIMENTAL
Intervention: Working memory
Number of subjects: 200
Study 36990481 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 200
Study 36990483 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditional Cash Transfer (CCT)
Number of subjects: 26
Study 36990483 — intervention group
Group type: COMPARATOR
Intervention: Control (No CCT)
Number of subjects: 26
Study 36990493 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic risk prediction models incorporating adverse events and medications
Number of subjects: 23887